Patent US4181731A successfully refreshed from Google Patents.
US4181731A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel therapeutic application of 4-carbamoyl-5-hydroxyimidazole
Assignee: Sumitomo Chemical Co Ltd
•
Filing: 1978-06-22
•
Granted: 1980-01-01
•
Expires: 1998-06-22
Abstract
Abstract 4-Carbamoyl-5-hydroxyimidazole representable by the following formula: <IMAGE> and pharmaceutically acceptable salts thereof have been found to be useful as therapeutic agents for the treatment of rheumatism and nephritis.
Inventors
- 👤 Noboru Yoshida
- 👤 Takao Kiyohara
- 👤 Shigeo Ogino
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:01
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/415
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
48 words
A method for the treatment of rheumatism and nephritis which comprises administering a composition containing an effective anti-rheumatic or anti-nephritic amount of 4-carbamoyl-5-hydroxyimidazole or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent to a patient suffering from rheumatism or nephritis.
Claim 2
Independent Claim
48 words
A method for the treatment of rheumatism and nephritis which comprises administering a composition containing an effective anti-rheumatic or anti-nephritic amount of 4-carbamoyl-5-hydroxyimidazole or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent to a patient suffering from rheumatism or nephritis.
Claim 3
Independent Claim
42 words
A method for the treatment of rheumatism which comprises administering to a patient suffering from rheumatism a composition comprising an effective anti-rheumatic amount of 4-carbamoyl-5-hydroxyimidazole or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent.
Claim 4
Independent Claim
42 words
A method for the treatment of rheumatism which comprises administering to a patient suffering from rheumatism a composition comprising an effective anti-rheumatic amount of 4-carbamoyl-5-hydroxyimidazole or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent.
Claim 5
Dependent Claim
20 words
A method according to claim 2, wherein said pharmaceutically acceptable salt of 4-carbamoyl-5-hydroxyimidazole is the hydrochloride or sodium salt thereof.
Claim 6
Dependent Claim
21 words
A method according to claim 2, wherein said composition is in the form of an injectable composition, tablet, capsule or suppository.
Claim 7
Dependent Claim
24 words
A method according to claim 2, wherein the daily dosage of the active ingredient is from 0.3 to 10 grams for an adult person.
Claim 8
Independent Claim
42 words
A method for the treatment of nephritis which comprises administering to a patient suffering from nephritis a composition comprising an effective anti-nephritic amount of 4-carbamoyl-5-hydroxyimidazole or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent.
Claim 9
Independent Claim
42 words
A method for the treatment of nephritis which comprises administering to a patient suffering from nephritis a composition comprising an effective anti-nephritic amount of 4-carbamoyl-5-hydroxyimidazole or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent.
Claim 10
Dependent Claim
20 words
A method according to claim 6, wherein said pharmaceutically acceptable salt of 4-carbamoyl-5-hydroxyimidazole is the hydrochloride or sodium salt thereof.
Claim 11
Dependent Claim
21 words
A method according to claim 6, wherein said composition is in the form of an injectable composition, tablet, capsule or suppository.
Claim 12
Dependent Claim
24 words
A method according to claim 6, wherein the daily dosage of the active ingredient is from 0.3 to 10 grams for an adult person.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-12-31 | 1983-07-02 | 1984-01-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-12-31 | 1987-07-02 | 1988-01-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-12-31 | 1991-07-02 | 1992-01-01 | $7700.00 | Window Closed / Lapsed |